| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -183.2 | -3.4 |
| EPS (diluted, $ a share) | $-61.58 | $-1.81 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PCSA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Processa Pharmaceuticals, Inc.: key numbers
- Share price
- $1.72Close, Nov 16
- Market cap
- $4.81M
- Shares outstanding
- 2.8MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Processa Pharmaceuticals, Inc.
All →Processa Pharmaceuticals Business Update
Processa Pharmaceuticals issued a stockholder letter outlining its strategic shift toward immunological and inflammatory (I&I) diseases following its July acquisition of Vidya Therapeutics. The company highlighted the advancement of its lead BTK inhibitor candidate, VT-7208, into Phase 2 development for food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis, supported by approximately $183.3 million in net cash proceeds.
Processa Pharmaceuticals Executive Compensation
Processa Pharmaceuticals appointed Gregory J. Flesher as Chief Operating Officer, effective November 4, 2026. Mr. Flesher will receive an annual base salary of $700,000, a target bonus of up to 60%, and an initial stock option grant representing 3.0% of the company's fully-diluted capital stock, contingent on shareholder approval of a new equity incentive plan.
Processa Pharmaceuticals Regulatory Approval
Processa Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for VT-7208, allowing the company to initiate a Phase 2 study in patients with chronic spontaneous urticaria. The company also appointed Dr. Sheila Gujrathi as Executive Chair and entered into a research collaboration with Generian Pharmaceuticals to expand its pipeline.
Processa Pharmaceuticals M&A Deal with Vidya Therapeutics, Inc.
Processa Pharmaceuticals filed an amendment to its 8-K to provide audited financial statements and pro forma information following its acquisition of Vidya Therapeutics. The deal adds VT7208, a CNS-penetrant BTK inhibitor, to Processa's pipeline for the treatment of autoimmune conditions like multiple sclerosis and food allergies.
- Counterparty
- Vidya Therapeutics, Inc.